| Autor: |
Maria T. Bourlon, Yuly A. Remolina-Bonilla, Aldo A. Acosta-Medina, Bruno I. Saldivar-Oviedo, Antonio Perez-Silva, Nayeli Martinez-Ibarra, Francisco Javier Castro-Alonso, Ana E. Martín-Aguilar, Samuel Rivera-Rivera, Fernando Mota-Rivero, Perla Pérez-Pérez, María G. Díaz-Alvarado, José M. Ruiz-Morales, Saúl Campos-Gómez, Bertha Alejandra Martinez-Cannon, Elaine T. Lam, Nora Sobrevilla-Moreno |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2023.1229016 |
| Popis: |
IntroductionThe survival of patients with metastatic renal cell carcinoma (mRCC) has improved dramatically due to novel systemic treatments. However, mRCC mortality continues to rise in Latin America.MethodsA retrospective, multicenter study of patients diagnosed with mRCC between 2010-2018 in Mexico City was conducted. The aim of the study was to evaluate the impact of healthcare insurance on access to treatment and survival in patients with mRCC.ResultsAmong 924 patients, 55.4%, 42.6%, and 1.9% had no insurance (NI), social security, (SS) and private insurance (PI), respectively. De novo metastatic disease was more common in NI patients (70.9%) compared to SS (47.2%) and PI (55.6%) patients (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
